Show simple item record

dc.contributor.authorHarvey, Brian H.
dc.contributor.authorSlabbert, Francois N.
dc.date.accessioned2016-02-02T12:20:37Z
dc.date.available2016-02-02T12:20:37Z
dc.date.issued2014
dc.identifier.citationHarvey, B.H. & Slabbert, F.N. 2014. New insights on the antidepressant discontinuation syndrome. Human psychopharmacology: clinical and experimental, 29:503-516. [https://doi.org/10.1002/hup.2429]en_US
dc.identifier.issn0885-6222
dc.identifier.issn1099-1077 (Online)
dc.identifier.urihttp://hdl.handle.net/10394/16111
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/abs/10.1002/hup.2429
dc.identifier.urihttps://doi.org/10.1002/hup.2429
dc.description.abstractObjective Antidepressants are at best 50–55% effective. Non-compliance and the antidepressant discontinuation syndrome (ADS) are causally related yet poorly appreciated. While ADS is associated with most antidepressants, agomelatine seems to be devoid of such risk. We review the neurobiology and clinical consequences of antidepressant non-compliance and the ADS. Agomelatine is presented as a counterpoint to learn more on how ADS risk is determined by pharmacokinetics and pharmacology. Design The relevant literature is reviewed through a MEDLINE search via PubMed, focusing on agomelatine and clinical and preclinical research on ADS. Results Altered serotonergic dysfunction appears central to ADS so that how an antidepressant targets serotonin will determine its relative risk for inducing ADS and thereby affect later treatment outcome. Low ADS risk with agomelatine versus other antidepressants can be ascribed to its unique pharmacokinetic characteristics as well as its distinctive actions on serotonin, including melatonergic, monoaminergic and glutamatergic-nitrergic systems. Conclusions This review raises awareness of the long-term negative aspects of non-compliance and inappropriate antidepressant discontinuation, and suggests possible approaches to “design-out” a risk for ADS. It reveals intuitive and rational ideas for antidepressant drug design, and provides new thoughts on antidepressant pharmacology, ADS risk and how these affect long-term outcomeen_US
dc.description.sponsorshipSouth African Medical Research Councilen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.subjectHalf-lifeen_US
dc.subjectAnhedoniaen_US
dc.subjectSerotonin transporteren_US
dc.subjectPhasic receptor occupancyen_US
dc.subjectNeuroplasticityen_US
dc.titleNew insights on the antidepressant discontinuation syndromeen_US
dc.typeArticleen_US
dc.contributor.researchID11083417 - Harvey, Brian Herbert
dc.contributor.researchID20182945 - Slabbert, Francois Naude


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record